Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Michael Osherov"'
Autor:
Leslie Menendez, Michael Osherov, Zeev Nitsan, Marwan Alkrenawi, Anna Gelfand, Nurit Hovel, Shmuel Appel, Ron Milo
Publikováno v:
Multiple Sclerosis and Related Disorders. 74:104692
Autor:
Shmuel Appel, Marwan Alkrenawi, Jonathan Droujin, Michael Osherov, Ron Milo, Azaria Simonovich
Publikováno v:
Neuroradiol J
Background Cervical discopathy and demyelinating lesions often co-exist in patients with multiple sclerosis (MS). Our study examines the possible association between these two pathologies. Methods Medical records and cervical magnetic resonance imagi
Autor:
Joab Chapman, Shmuel Appel, Michael Osherov, Zeev Nitsan, Hanna Rosenmann, Amos D. Korczyn, Ron Milo, Oren S. Cohen, Esther Kahana
Publikováno v:
Journal of Neurology. 267:2455-2458
To characterize the demographic, clinical features and disease course of familial Creutzfeldt–Jakob disease (fCJD) patients homozygous to the E200K mutation. The Israeli National CJD Database was screened for patients homozygous to the E200K mutati
Autor:
Paul S. Giacomini, Maryam Sharifian-Dorche, Jack P. Antel, Giulia Fadda, Michael Osherov, Amirhossein Sharifian-Dorche, Mohammad Ali Sahraian, Roberta La Piana, Alexander Saveriano, Maryam Karaminia
Publikováno v:
Multiple Sclerosis and Related Disorders
Introduction The Coronavirus disease-19 (COVID-19) pandemic continues to expand across the world. This pandemic has had a significant impact on patients with chronic diseases. Among patients with demyelinating diseases of the central nervous system (
Autor:
Ron Milo, Michael Osherov
Publikováno v:
Expert Review of Clinical Pharmacology. 10:1037-1047
The goal of the article is to review the mechanism of action and the use of daclizumab, a humanized monoclonal antibody (mAb) against the alpha subunit of the high affinity interleukin-2 (IL-2) receptor, in the treatment of Multiple Sclerosis (MS). A
Publikováno v:
American Journal of Otolaryngology. 39:410-412
Purpose The objective of this study is to examine the rate of horizontal canal BPPV recurrence of the same type and search for predisposing factors.
Autor:
Zeev, Nitsan, Oren S, Cohen, Joab, Chapman, Esther, Kahana, Amos D, Korczyn, Shmuel, Appel, Michael, Osherov, Hanna, Rosenmann, Ron, Milo
Publikováno v:
Journal of neurology. 267(8)
To characterize the demographic, clinical features and disease course of familial Creutzfeldt-Jakob disease (fCJD) patients homozygous to the E200K mutation.The Israeli National CJD Database was screened for patients homozygous to the E200K mutation.
Autor:
Michael Osherov, Ron Milo
Publikováno v:
Emerging Drugs and Targets for Multiple Sclerosis ISBN: 9781788014502
The traditional view of multiple sclerosis (MS) as a T cell mediated autoimmune disease of the central nervous system (CNS) has evolved into a concept of an immune-mediated disease where complex bi-directional interactions between T cells, B cells an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5725ef4d9f3534d318fafbcd20efc74
https://doi.org/10.1039/9781788016070-00134
https://doi.org/10.1039/9781788016070-00134
Autor:
Alexander Saveriano, Paul S. Giacomini, Philippe Huot, Michael Osherov, Maryam Sharifian-Dorche, Dingke Wen, Ashkan Mowla, Jack P. Antel
Publikováno v:
Journal of the Neurological Sciences
Introduction Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. Several studies have been performed, focusing on understanding the acute respiratory syndrome and treatment strategies. However, there is growing evidence i
Autor:
Ron Milo, Michael Osherov
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 53(1)
Daclizumab is a humanized monoclonal antibody that binds to the a-subunit (CD25) of the interleukin-2 receptor (IL-2R), thus blocking the formation of the high-affinity IL-2R which is expressed mainly on activated and regulatory T cells. IL-2R modula